Table 2.

Frequency by inflammation grade and association of clinical characteristics with tumor inflammation grade ≥1 in men undergoing RP

Inflammation gradeOR (95% CI)P
0 (%)≥1 (%)
Statin medication usage*
    Nonusers34 (81)165 (85)Reference
    <1 DE1 (2)9 (5)1.30 (0.08-22.02)0.86
    ≥1 DE7 (17)20 (10)0.22 (0.06-0.79)0.02
Race
    Caucasian18 (43)105 (54)Reference
    African American22 (52)87 (45)0.64 (0.25-1.61)0.34
    Other2 (5)2 (1)0.22 (0.01-4.14)0.31
BMI (kg/m2)
    <2512 (31)56 (34)Reference
    25-29.916 (42)63 (38)0.93 (0.32-2.71)0.89
    30-34.99 (24)37 (23)0.58 (0.16-2.02)0.39
    ≥351 (3)8 (5)0.99 (0.07-14.09)0.99
Clinical stage
    T1c30 (77)104 (56)Reference
    T2/T39 (23)81 (44)3.42 (1.17-10.03)0.025
NSAID use before RP26 (62)115 (59)1.09 (0.41-2.87)0.87
Pathology Gleason sum
    2-612 (29)30 (15)Reference
    726 (62)143 (74)1.43 (0.45-4.54)0.55
    8-104 (9)21 (11)0.45 (0.07-2.87)0.40
Extracapsular extension5 (12)57 (30)3.42 (0.82-14.27)0.09
Positive surgical margins20 (48)133 (69)2.00 (0.80-5.03)0.14
Seminal vesicle invasion2 (5)34 (18)4.79 (0.44-52.12)0.20

NOTE: Data were obtained by using logistic regression controlling for age, year of surgery, time interval from biopsy to surgery, and prostate weight in addition to parameters listed in the table.

  • *Usage of statin medication was expressed in DE terms, with simvastatin 20 mg as 1 DE.